Phaseline

Companies › Anavex Life Sciences

Anavex Life Sciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ANAVEX3-71
Dual SIGMAR1 receptor agonist and M1 positive allosteric modulator
SIGMAR1, CHRM1Phase 2Schizophrenia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06245213ANAVEX3-71Phase 2SchizophreniaPsychiatryJun 2025

From the company's SEC filings

Cash of $118m on 2026-06-30; operating cash outflow about $28m a year; runway about 51 months at that burn, to Oct 2030

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

SIGMAR1 (1) CHRM1 (1)

Companies with the same targets

Exciva Bristol-Myers Squibb UCB BIOSCIENCES Pentixapharm Zogenix CSPC Ouyi Pharmaceutical Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ocus Innovation Ireland Novartis AstraZeneca

Companies built like this

Seaport Therapeutics Definium Therapeutics US NeuroRx Bazelet Nehushtan Autobahn Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.